Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of apatinib in the treatment of metastatic penile cancer

Trial Profile

Phase II trial of apatinib in the treatment of metastatic penile cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Penile cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 16 Feb 2019 9 patients were enrolled from October 2016 to May 2018, and eight patients were eligible for efficacy analysis as per trial design presented at the 2019 Genitourinary Cancers Symposium
  • 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium
  • 13 May 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top